About half of melanomas carry an activating somatic mutation in the BRAF gene, often a valine to glutamate substitution at amino acid 600 (V600E). N-ras is mutated in about 20% and rare pts have activating mutations in c-kit. These mutations have been targeted by therapeutic agents that have antitumor activity.